Pipeline Trigger: Predicta Biosciences $23.4M Series A

🚀 Battle Card: Predicta Biosciences

• Brian McKernan, CEO · 🔗 [LinkedIn](https://www.linkedin.com/in/brian-mckernan-0546617/)

• New capital accelerates scaling of non-invasive oncology diagnostics and lab infrastructure, signaling aggressive expansion into precision diagnostics. → Source

• Rapidly scale CLIA lab infrastructure without compromising compliance

• Commercialize GenoPredicta while expanding diagnostic portfolio

• Primary: Lab automation & integration platform → increase throughput & ensure CLIA compliance

• Expansion: Data analytics & reporting suite → deliver actionable patient insights & differentiation

• HQ: Cambridge, MA

• Employees: ≈ 75

• Rev: ≈ $5M

• Website: [predictabiosciences.com](https://www.predictabiosciences.com/)

🤼 Competitive Intel

• Guardant Health — Liquid biopsy diagnostics
• Unique edge: Widely adopted ctDNA assays
• Evaluated by Dir. R&D for clinical validation

• Foundation Medicine — Comprehensive genomic profiling
• Unique edge: Deep tumor sequencing & FDA approvals
• Evaluated by VP Ops for regulatory fit

• Natera — Molecular diagnostics & testing
• Unique edge: Proven workflow in clinical labs
• Evaluated by Lab Manager for throughput

• Grail — Early cancer detection
• Unique edge: NGS-based multi-cancer early detection
• Evaluated by CMO for pipeline alignment

• Invitae — Genetic testing services
• Unique edge: Comprehensive test menu & payer coverage
• Evaluated by CFO for cost structure

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑❑
OFFER_BRIEF   = ❑Lab automation & integration platform❑
PROOF_METRIC  = ❑40% throughput boost❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑punchy❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Brian
COMPANY     = Predicta Biosciences
DEPT        = Ops & Supply Chain
SIZE        = ≈10
BOTTLENECK  = Rapidly scaling CLIA lab infrastructure without compliance risks
EVENT       = $23.4M Series A raise
DETAIL      = scale its novel diagnostic platform
PAIN        = difficulty scaling CLIA labs without errors or compliance
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251001161796&div=41152219
SIM_CO      = Guardant Health
WIN_METRIC  = 40% throughput boost
NEXT_SIZE   = ≈20
EMP_EST     = ≈75
REV_EST     = ≈$5M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈10-person Ops & Supply Chain

Brian—noticed your Ops & Supply Chain team is ≈10.

That’s when Rapidly scaling CLIA lab infrastructure without compliance risks slows growth.

We helped Guardant Health fix this with Lab automation & integration platform.

Result: 40% throughput boost.  
Quick call?

PS—next bottleneck hits ≈20.

DM ≤45 words, TONE:
Saw your post about scale its novel diagnostic platform — difficulty scaling CLIA labs without errors or compliance.  
Lab automation & integration platform. 40% throughput boost.  
Quick chat?